Peijia Medical Limited (HKG:9996)
Hong Kong · Delayed Price · Currency is HKD 4.020
+0.020 (0.50%)
Jul 31, 2026, 4:08 PM HKT
Peijia Medical Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 712.87 | 712.87 | 615.48 | 441.13 | 250.83 | 136.53 |
Revenue Growth | 6.77% | 15.82% | 39.52% | 75.86% | 83.71% | 253.21% |
Gross Profit Gross Profit Growth | 486.05 | 486.05 | 433.62 | 325.37 | 176.2 | 95.65 |
Operating Income Operating Income Growth | -196.14 | -196.14 | -229.7 | -327.03 | -323.12 | -235.87 |
Net Income Net Income Growth | -203.29 | -203.29 | -226.58 | -392.53 | -407.81 | -574.22 |
Earnings Per Share EPS Growth | -0.31 | -0.31 | -0.34 | -0.58 | -0.61 | -0.87 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Transcatheter Valve Therapeutic Business Transcatheter Valve Therapeutic Business Growth | 290.09 | 290.09 | 259.94 | 185.57 | 107.31 | 41.94 |
Neurointerventional Business Neurointerventional Business Growth | 422.78 | 422.78 | 355.55 | 255.56 | 143.52 | 94.59 |
Total Total Growth | 712.87 | 712.87 | 615.48 | 441.13 | 250.83 | 136.53 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 560.26 | 560.26 | 712.52 | 942.93 | 1,743 | 2,298 |
Total Debt Total Debt Growth | 434.03 | 434.03 | 253.4 | 221.14 | 131.88 | 7.63 |
Net Cash (Debt) Net Cash Growth | 126.23 | 126.23 | 459.12 | 721.79 | 1,611 | 2,290 |
Net Cash Growth | -54.84% | -72.51% | -36.39% | -55.20% | -29.65% | -6.68% |
Net Cash Per Share Net Cash Per Share Growth | 0.19 | 0.19 | 0.69 | 1.06 | 2.39 | 3.46 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -20.89 | -20.89 | -5.18 | -630.91 | -376.2 | -436.37 |
Capital Expenditures CapEx Growth | -231.59 | -231.59 | -249.14 | -175.62 | -130.41 | -69.74 |
Free Cash Flow Free Cash Flow Growth | -252.48 | -252.48 | -254.32 | -806.54 | -506.61 | -506.11 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 68.18% | 68.18% | 70.45% | 73.76% | 70.25% | 70.06% |
Operating Margin | -27.51% | -27.51% | -37.32% | -74.13% | -128.82% | -172.75% |
Pretax Margin | -28.42% | -28.42% | -36.00% | -88.75% | -158.76% | -420.57% |
Profit Margin | -28.52% | -28.52% | -36.81% | -88.98% | -162.58% | -420.57% |
FCF Margin | -35.42% | -35.42% | -41.32% | -182.84% | -201.97% | -370.68% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Aug '26 Aug 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 3.39 | 5.07 | 3.98 | 10.27 | 22.67 | 53.17 |